Key Highlights

  • Citius Pharmaceuticals shares tumbled 26% to end the day at $0.56.
  • The company posted a GAAP net loss of $0.34 per share, $0.09 wider than anticipated.
  • Revenue of $1.5 million fell $8.27 million short of consensus.
  • The company's cash balance stood at $17.0 million as it navigates the initial commercial launch of LYMPHIR.

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) shares tumbled 26% to end the day at $0.56 after the company reported third-quarter financial results that missed the mark, posting a GAAP net loss of $0.34 per share, which was $0.09 wider than anticipated.

What Happened

The company's Revenue of $1.5 million fell $8.27 million short of consensus. With a cash balance of $17.0 million, the company faces continued funding needs while navigating the initial commercial launch phase for LYMPHIR.

Market Reaction

Shares tumbled sharply as investors focused on the scale of both the Earnings and revenue misses, alongside the company's continued funding needs as it works through the early stages of its commercial launch.

Outlook

Continued progress on the commercial launch of LYMPHIR, weighed against Citius Pharmaceuticals' $17.0 million cash position and ongoing funding needs, is likely to remain the key Factor shaping sentiment toward the stock going forward.